IP Library Granted Patent US 8,440,223
Granted Patent B2
US 8,440,223 · App. 13/002,277 · Granted May 14, 2013

Sustained release pharmaceutical compositions comprising quetiapine in non-gellable polymers

Inventors: Avinash Krishnaji Velhal (Pune, IN); Sunil Anantrao Mirajkar (Pune, IN); Virendra Ramkrupal Kuril (Pune, IN); Vineeth Raghavan (Pune, IN); Ninad Deshpanday (Pune, IN)
Assignee: Lupin Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,223
App. No.
13/002,277
Granted
May 14, 2013
Kind
B2
Abstract

A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form. A sustained release dosage form comprising immediate release core comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more pharmaceutically acceptable excipients; and sustained release coating comprising one or more non-gellable release controlling material.

Claims (11)

1. A sustained release dosage form consisting essentially of:

Quetiapine or a pharmaceutically acceptable salt, polymorph, solvate, or hydrate thereof;

one or more non-gellable release controlling polymer; and

one or more pharmaceutically acceptable excipient(s).

2. The sustained release dosage form as in claim 1 wherein the dosage form comprises the drug in the matrix.

3. The sustained release dosage form as in claim 1 wherein the dosage form includes tablets, capsules, pellets, granules.

4. The sustained release dosage form as in claim 1 wherein the non-gellable release controlling polymer is selected from the group comprising cellulose acetate, acrylic polymer such as Poly (ethyl acrylate, methyl methacrylate) polymer, ammonio methacrylate copolymers.

5. The sustained release dosage form of claim 1 , consisting of:

Quetiapine or a pharmaceutically acceptable salt, polymorph, solvate, or hydrate thereof;

one or more non-gellable release controlling polymers; and

one or more pharmaceutically acceptable excipient(s).

Assignments (2)
CHANGE OF ADDRESS Recorded Jan 27, 2017
From: LUPIN LIMITED
To: LUPIN LIMITED
Reel/Frame 041936/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2011
From: VELHAL, AVINASH KRISHNAJI; MIRAJKAR, SUNIL ANANTRAO; KURIL, VIRENDRA RAMKRUPAL; RAGHAVAN, VINEETH; DESHPANDAY, NINAD
To: LUPIN LIMITED
Reel/Frame 025739/0502 →
Priority Claims (1)
IN 1143/KOL/2008 · Jul 1, 2008 · national
Continuity (1)
Related Publication 20110151002A1 · Jun 23, 2011